Anna Minchom, MBBCh, MRCP, MD(Res), discusses updated safety results from the PALOMA trial and the identified recommended phase 2 dose for subcutaneous biweekly administration of amivantamab for patients with advanced solid malignancies.
Anna Minchom, MBBCh, MRCP, MD(Res), discusses updated safety results from the PALOMA trial and the identified recommended phase 2 dose for subcutaneous biweekly administration of amivantamab for patients with advanced solid malignancies.
Anna Minchom, MBBCh, MRCP,...